Peanut Allergy

Peanut Allergy

Protocol Number: UKKO-18-101-ANZ

About this Clinical Study

About this Clinical Study

This clinical study is testing an investigational treatment for peanut allergy. The study aims to understand how safe the treatment is and how the immune system responds to it in adults with a confirmed peanut allergy.

The treatment being studied is not approved and is only available through this research study. It has not been given to people before, which is why the study includes close medical monitoring and detailed safety assessments.

The study involves specialist doctors and trained clinical staff, and all procedures are conducted in a controlled clinical environment. Participation is voluntary, and choosing not to take part will not affect your usual medical care.
This study has been reviewed and approved by an independent Human Research Ethics Committee.

Learn More

Who Can Take Part?

Who Can Take Part?

You may be eligible to take part if you:

Are 18 to 55 years old
Have a doctor-diagnosed peanut allergy
Have had allergy testing (such as a skin prick test or blood test) confirming peanut allergy
Are able to attend multiple clinic visits over several months
Are willing to undergo medically supervised allergy testing as part of the study
Have access to an in-date adrenaline (epinephrine) auto-injector

You cannot take part if you:

You cannot take part if you:

• Have had a recent severe or life-threatening allergic reaction

• Have a history of serious reactions to mRNA vaccines

• Have had myocarditis or pericarditis

• Are currently pregnant or breastfeeding

• Are unable to safely stop certain allergy medications before testing

• Are unable to commit to the required clinic visits and follow-up

Final eligibility is determined by the study doctor after screening assessments.

Learn More

What’s Involved

What’s Involved

If you take part, your involvement may include:

An initial screening period to confirm eligibility

A medically supervised peanut food challenge to assess your allergy level

Up to three intramuscular injections of the investigational study treatment over time

Short periods of in-clinic monitoring, including one overnight stay after the first dose

Regular follow-up visits, blood tests, and health checks

A second supervised peanut food challenge later in the study

Ongoing safety monitoring throughout the study

The total study duration is approximately 5 to 9 months, depending on the dosing schedule.
You can withdraw from the study at any time without giving a reason.